NCT01306929View on ClinicalTrials.gov

Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

March 24, 2011

Primary Completion Date

January 5, 2018

Study Completion Date

January 5, 2018

Conditions
Huntington Disease
Interventions
DRUG

pridopidine

45mg bid

Sponsors

Lead Sponsor

Prilenia
All Listed Sponsors
lead

Prilenia

INDUSTRY